Literature DB >> 24587824

Tolcapone addition improves Parkinson's disease associated nonmotor symptoms.

Thomas Müller1.   

Abstract

BACKGROUND: Addition of catechol-O-methyltransferase inhibitors to a conventional levodopa/dopadecarboxylase inhibitor regimen improves motor symptoms in patients with Parkinson's disease. Optimizing dopamine substitution is also beneficial for nonmotor features.
OBJECTIVES: To investigate the efficacy of supplemental tolcapone intake on nonmotor symptoms. DESIGN/
METHODS: A total of 125 levodopa-treated patients additionally took tolcapone in this observational trial. Initially and following 4 weeks of tolcapone intake, the neurologist scored with Unified Parkinson's Disease Rating Scale parts I, II, IV, the nonmotor symptoms scale for Parkinson's disease and recorded the off time. The patients rated themselves with the EuroQuol, its visual analogue scale and the nonmotor screening questionnaire. Caregivers reported the daily duration of care giving.
RESULTS: All scores improved except for Unified Parkinson's Disease Rating Scale part IV and domains 4, 5 and 8 of the nonmotor symptoms scale for Parkinson's disease.
CONCLUSION: This trial demonstrates that tolcapone addition may improve nonmotor features.

Entities:  

Keywords:  Parkinson’s disease; nonmotor symptoms; tolcapone

Year:  2014        PMID: 24587824      PMCID: PMC3932768          DOI: 10.1177/1756285613512392

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  19 in total

1.  Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.

Authors:  M Fava; J F Rosenbaum; A R Kolsky; J E Alpert; A A Nierenberg; M Spillmann; C Moore; P Renshaw; T Bottiglieri; G Moroz; G Magni
Journal:  J Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.153

2.  The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

3.  International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

4.  Cognitive improvement during Tolcapone treatment in Parkinson's disease.

Authors:  M Gasparini; E Fabrizio; V Bonifati; G Meco
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.

Authors:  H Russ; T Müller; D Woitalla; A Rahbar; J Hahn; W Kuhn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-12       Impact factor: 3.000

6.  Quality of life in Parkinson's disease patients following adjunctive tolcapone therapy: results of an open-label, multicenter, community-based trial.

Authors:  Kapil Sethi; Stewart Factor; Ray Watts
Journal:  CNS Spectr       Date:  2010-01       Impact factor: 3.790

7.  Tolcapone: a potential new antidepressant detected in a novel animal model of depression.

Authors:  J.-L. Moreau; J. Borgulya; F. Jenck; J.R. Martin
Journal:  Behav Pharmacol       Date:  1994-06       Impact factor: 2.293

8.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

9.  Dopamine, corticostriatal connectivity, and intertemporal choice.

Authors:  Andrew S Kayser; Daicia C Allen; Ana Navarro-Cebrian; Jennifer M Mitchell; Howard L Fields
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

10.  Nonmotor fluctuations in Parkinson's disease: frequent and disabling.

Authors:  Tatiana Witjas; E Kaphan; J P Azulay; O Blin; M Ceccaldi; J Pouget; M Poncet; A Ali Chérif
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

View more
  7 in total

1.  Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-02-01       Impact factor: 3.575

2.  Benefit on motor and non-motor behavior in a specialized unit for Parkinson's disease.

Authors:  Thomas Müller; Gabi Öhm; Kathrin Eilert; Katharina Möhr; Stephanie Rotter; Thomas Haas; Matthias Küchler; Sven Lütge; Marion Marg; Hartmut Rothe
Journal:  J Neural Transm (Vienna)       Date:  2017-02-28       Impact factor: 3.575

Review 3.  COMT Inhibitors in the Management of Parkinson's Disease.

Authors:  Margherita Fabbri; Joaquim J Ferreira; Olivier Rascol
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

4.  Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.

Authors:  Ingrid Buchler; Daniel Akuma; Vinh Au; Gregory Carr; Pablo de León; Michael DePasquale; Glen Ernst; Yifang Huang; Martha Kimos; Anna Kolobova; Michael Poslusney; Huijun Wei; Dominique Swinnen; Florian Montel; Florence Moureau; Emilie Jigorel; Monika-Sarah E D Schulze; Martyn Wood; James C Barrow
Journal:  J Med Chem       Date:  2018-10-19       Impact factor: 7.446

5.  Safety and efficacy of tolcapone in Parkinson's disease: systematic review.

Authors:  Carlo Alberto Artusi; Lidia Sarro; Gabriele Imbalzano; Margherita Fabbri; Leonardo Lopiano
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

6.  Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol O-Methyltransferase.

Authors:  Glen Ernst; Daniel Akuma; Vinh Au; Ingrid P Buchler; Spencer Byers; Gregory V Carr; Sabine Defays; Pablo de León; Thierry Demaude; Michael DePasquale; Véronique Durieu; Yifang Huang; Emilie Jigorel; Martha Kimos; Anna Kolobova; Florian Montel; Florence Moureau; Michael Poslusney; Dominique Swinnen; Marie-Christine Vandergeten; Nathalie Van Houtvin; Huijun Wei; Noelle White; Martyn Wood; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2019-10-22       Impact factor: 4.345

7.  Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.

Authors:  Diego Santos García; Gustavo Fernández Pajarín; Juan Manuel Oropesa-Ruiz; Francisco Escamilla Sevilla; Raúl Rashid Abdul Rahim López; José Guillermo Muñoz Enríquez
Journal:  Brain Sci       Date:  2022-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.